
Please try another search
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Name | Age | Since | Title |
---|---|---|---|
Peter Sage Knight | 74 | 2018 | Independent Director |
Gary Rubin | 68 | 2017 | Independent Director |
Steven Girgenti | 79 | 2014 | Founder & Executive Chairman of the Board |
Robert A. Anderson | 85 | 2014 | Independent Director |
Catherine Sears | - | - | Member of Science & Medical Advisory Board |
Gerard A. Silvestri | - | - | Member of Science & Medical Advisory Board |
Maria Zannes | 69 | 2014 | Founder, President, CEO & Director |
Neil Alexis | - | - | Member of Science & Medical Advisory Board |
Roby Paul Joyce | 78 | 2023 | Director |
Sandeep Bansal | - | 2024 | Member of Science & Medical Advisory Board |
David G. Hill | - | 2022 | Member of Science & Medical Advisory Board |
Sheila Habib | - | 2022 | Member of Scientific & Medical Advisory Board |
Stuart Diamond | 64 | 2022 | Independent Director |
Jamie Platt | 58 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review